CGEM
Cullinan Therapeutics, Inc.
NASDAQ · Healthcare · Medical - Pharmaceuticals · US
$15.45
−0.71%Price chart
Sep 30Oct 5Oct 8Oct 13Oct 16Oct 21Oct 26Oct 29
Key dataOct 29, 2026
Open$15.60
From 52W high−32.68%
Volume458848.00
Market cap$994.28M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 29, 2026
Open
$15.60
From 52W high
−32.68%
Volume
458848.00
Market cap
$994.28M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.2x
P/E (TTM)
—
RSI (14)
50.5
MomentumView details →
1D Return
−0.71%
YTD Return
+52.37%
SummaryUpdated Jun 1, 2026
Cullinan Oncology, Inc. (NASDAQ:CGEM) is a biopharmaceutical company founded in 2016 and headquartered in Cambridge, Massachusetts. The company went public in January 2021 and focuses on developing targeted oncology and immuno-oncology therapies for cancer patients. As a clinical-stage biotechnology company, Cullinan operates without generating revenue from product sales, instead relying on research and development activities to advance its pipeline of experimental cancer treatments through various stages of clinical trials.
Similar companies
Latest newsMore news →
Cullinan Therapeutics, Inc. announced that the first patient was dosed in its Phase 2 study of CLN-049 for relapsed or refractory acute myeloid leukemia.22d agoCullinan Therapeutics outlined fourth quarter 2026 milestones for its immunology and oncology T cell engager pipeline, including multi-dose data for velinotamig in SLE at ACR Convergence 2026 in November, CLN-978 data in SLE, RA and Sjögren's disease in December, and updated CLN-049 Phase 1 data in December.36d agoCullinan Therapeutics announced it will host a virtual analyst and investor event to showcase Phase 3 REZILIENT3 data for zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion mutation NSCLC, to be presented at the IASLC 2026 World Conference on Lung Cancer on September 13, 2026.49d ago